Regular Article

British Journal of Cancer (1999) 79, 1665–1671. doi:10.1038/sj.bjc.6690266 www.bjcancer.com
Published online 12 March 1999

In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines

R A M Al-Mufti1, R B Pedley2, D Marshall2, R H J Begent2, A Hilson3, M C Winslet1 and K E F Hobbs1

  1. 1Departments of Surgery, Royal Free Hospital, Pond Street, London, NW3 2QG, UK
  2. 2Departments of Clinical Oncology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK
  3. 3Departments of Nuclear Medicine, Royal Free Hospital, Pond Street, London, NW3 2QG, UK

Received 1 September 1997; Revised 18 May 1998; Accepted 7 August 1998.

Top

Abstract

Intra-arterial Lipiodol has been used to deliver targeted therapies to primary, and some metastatic, liver cancers. Targeted radiotherapy has been used by substituting the iodine in Lipiodol with 131Iodine (131I). Early clinical results are encouraging, but the variable response may partly depend on local pharmacokinetics. This study evaluated the in vitro cytotoxic effects of 131I-Lipiodol on human hepatocellular carcinoma (Hep-G2), human colorectal metastatic cancer (SW620), human colorectal hepatic cancer (LoVo) and human umbilical vein endothelial cells (HUVEC) cell lines. The cell cultures were exposed to 131I-Lipiodol for 48 h, following which cell counts and viability were assessed by haemocytometer, S-Rhodamine uptake and radioactivity assay. The effect of exposure to control Lipiodol, 131I-Lipiodol and 131I alone was evaluated. 131I-Lipiodol was cytotoxic against all the cancer cell lines but not against the non-malignant (HUVEC) cell line. The cytotoxicity effects were very similar in all the cancer cell lines. There were no cytotoxic effects following exposure to plain 131I in any of the cell lines (malignant and non-malignant). A similar trend was seen with radioactivity counts using a gamma counter. The cytotoxic effect of 131I-Lipiodol had a graded effect with an increase in cytotoxicity following the increase in the radioactive dose. This study showed that there was a marked cytotoxic effect by 131I-Lipiodol on all the cancer cell lines. There was no difference between the controls and the 131Iodine. This suggests that effective 131I-Lipiodol targeted therapy is dependent on the uptake and retention of Lipiodol by malignant cells.

Keywords:

Lipiodol therapy, targeted radiotherapy, primary liver cancer, colorectal liver metastases, in-vitro cytotoxicity

Top

References

  1. ABPI Data Sheet Compendium (1991-1992). The Pharmaceutical Industry, compiled by G Walker, pp. 1199. Datapharm; London
  2. Al-Mufti, R., Bhattacharya, S., Novell, J. R., Winslet, M. C. & Hobbs, K. E. F. (1995a). Intra-arterial radiotherapy with Lipiodol-Iodine 131 for irresectable hepatocellular carcinoma. Br J Cancer 72: 19
  3. Al-Mufti, R., Bhattacharya, S., Lewin, J., Winslet, M. C. & Hobbs, K. E. F. (1995b). In vitro assessment of iodised oil (Lipiodol) uptake in primary and metastatic liver tumours. Br J Cancer 72: 38
  4. Al-Mufti, R. A. M., Bhattacharya, S., Winslet, M. C. & Hobbs, K. E. F. (1996a). Quantification of uptake and retention of iodised oil (Lipiodol) in primary and secondary hepatic malignancy (Abstract presentation). HPB Surgery 9: 72 [P006]
  5. Al-Mufti, R. A. M., Bhattacharya, S., Hobbs, K. E. F. & Winslet, M. C. (1996b). In-vitro assessment of the uptake of Lipiodol by liver tumours: is it a mechanism specific to Lipiodol? (Abstract). HPB Surgery 9: 72 [P005]
  6. Bhattacharya, S., Dhillon, A. P., Winslet, M. C., Davidson, B. R., Shukla, N., Datta Gupta, S., Al-Mufti, R. A. M. & Hobbs, K. E. F. (1996). Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 73: 877–881.
  7. BP (1993). The British Pharmacopoeia 1993, Volume II, pp. 967. Published on the Recommendation of the Medicines Commission Pursuant to the Medicines Act 1968. HMSO: London
  8. Bretagne, J-F, Raoul, J-L, Bourget, P., Duvauferrier, R., Deugneir, Y., Faroux, R., Ramée, A., Herry, J-Y & Gastard, J. (1988). Hepatic artery injection of I-131 labelled lipiodol part II: preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 168: 547–550. | PubMed | ISI | ChemPort |
  9. Chatin, I. & Bonnrmain, B. (1992). Composition de Lipiodol Ultra Fluide. Laboratoire Guerbet: France
  10. Chou, F. I., Lui, W. Y., Chi, C. W. & Chan, W. K. (1994). 131I-Lipiodol cytotoxicity in hepatoma cells. Proceedings of the National Science Council, ROC, Part B:. Life Sciences 18: 154–160.
  11. Drewinko, B., Romsdahl, M. M., Yang, L. Y., Ahearn, M. J. & Trujillo, J. M. (1976). Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. 36: 467–475
  12. Friedman, M. A. (1983). Primary hepatocellular cancer: present results and future prospects. Int J Radiat Oncol Biol Phys 9: 1841–1850.
  13. Jaffe, E. A. (1987). Cell biology of endothelial cells. Hum Pathol 18: 234–239. | PubMed | ISI | ChemPort |
  14. Jaffe, E. A., Nachman, R. L. & Becker, C. G. (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745–2756. | Article | PubMed | ISI | ChemPort |
  15. Knowles, B. B., Howe, C. C. & Aden, D. P. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497–499. | Article | PubMed | ISI | ChemPort |
  16. Konno, T., Maeda, H. & Iwai, K. (1983). Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma. Eur J Cancer Clin Oncol 19: 1053–1965. | Article | PubMed | ISI | ChemPort |
  17. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M. & Miyauchi, Y. (1984). Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumours by arterially administered lipid contrast medium. Cancer 54: 2367–2374. | PubMed | ISI | ChemPort |
  18. Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C. & Mabry, N. D. (1976). Classification of human colorectal adenocarcinoma cell line. Cancer Res 36: 4562–4569. | PubMed | ISI | ChemPort |
  19. Madden, M. V., Krige, J. E. J., Bailey, S., Beningfield, S. J., Geddes, C., Werner, I. D. & Terblanche, J. (1993). Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 34: 1598–1600.
  20. Nakakuma, K., Tashiro, S. & Uemura, K. (1979). An attempt for increasing effects of hepatic artery ligation for advanced hepatoma (English abstract). Jap-Deutsche Med Beriehte 24: 675–682.
  21. Nakakuma, K., Tashiro, S., Hiraoka, T., Uemura, K., Konno, T., Miyauchi, Y. & Yokoyama, I. (1983). Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 52: 2193–2200. | PubMed | ISI | ChemPort |
  22. Novell, R., Hilson, A. & Hobbs, K. (1991). Ablation of recurrent primary liver cancer using 131I-Lipiodol. Postgrad Med J 67: 393–395.
  23. Raoul, J-L, Bourguet, P., Bretagne, J. F., Duvanferrier, R., Coornaet, S., Darnault, P., Rammée, Herry, J. Y. & Gastard, J. (1988). Hepatic artery injection of 131-I-labelled lipiodol. Part I: Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 168: 541–545. | PubMed | ISI | ChemPort |
  24. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S. & Boyd, M. R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112. | Article | PubMed | ChemPort |
  25. Vetter, D., Wenger, J-J, Bergier, J-M, Doffoel, M. & Bokel, R. (1991). Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 13: 427–433.